Biological activities of receptor-interacting protein 140 in adipocytes and metabolic diseases

Current Diabetes Reviews

Volumn 8, Issue 6, 2012, Pages 452-457

  Ho, Ping Chih ^a   Wei, Li Na ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Adipocyte; Adiponectin; Ambresentan; Biomarker; Endothelin 1 (Et 1); GLUT4; Nuclear translocation; Post translational modification (PTM); Rip140; Therapeutics; Type ii diabetes mellitus (T2dm)

Indexed keywords

RECEPTOR INTERACTING PROTEIN 140;

ACETYLATION; ADIPOCYTE; ARTICLE; BIOLOGICAL ACTIVITY; CONJUGATION; CYTOPLASM; HUMAN; METABOLIC DISORDER; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN METHYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION; SUMOYLATION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; BIOLOGICAL MARKERS; CYTOPLASM; DIET, HIGH-FAT; HUMANS; INSULIN RESISTANCE; METABOLIC SYNDROME X; METHYLATION; MICE; MICE, KNOCKOUT; NUCLEAR RECEPTOR CO-REPRESSOR 1; PHOSPHORYLATION; PROTEIN PROCESSING, POST-TRANSLATIONAL; SIGNAL TRANSDUCTION;

EID: 84870166469     PISSN: 15733998     EISSN: 18756417     Source Type: Journal    
DOI: 10.2174/157339912803529922     Document Type: Article

References (56)

1. Guilherme A, Virbasius JV, Puri V, Czech MP. Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes. Nat Rev Mol Cell Biol. 2008 May; 9(5): 367-77.
2. Fritah A, Steel JH, Nichol D, et al. Elevated expression of the metabolic regulator receptor-interacting protein 140 results in cardiac hypertrophy and impaired cardiac function. Cardiovasc Res. 2010 Jun 1; 86(3): 443-51.
3. McInnes IB, Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med. 2011 Dec 8; 365(23): 2205-19.
4. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002 Jan 16; 287(3): 356-9.
5. Leichman JG, Lavis VR, Aguilar D, Wilson CR, Taegtmeyer H. The metabolic syndrome and the heart--a considered opinion. Clin Res Cardiol. 2006 Jan; 95 Suppl 1: i134-41.
6. Zimmermann R, Lass A, Haemmerle G, Zechner R. Fate of fat: the role of adipose triglyceride lipase in lipolysis. Biochim Biophys Acta. 2009 Jun; 1791(6): 494-500.
7. Herman MA, Kahn BB. Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony. J Clin Invest. 2006 Jul; 116(7): 1767-75.
8. Antoniades C, Antonopoulos AS, Tousoulis D, Stefanadis C. Adiponectin: from obesity to cardiovascular disease. Obes Rev. 2009 May; 10(3): 269-79.
9. Dridi S, Taouis M. Adiponectin and energy homeostasis: consensus and controversy. J Nutr Biochem. 2009 Nov; 20(11): 831-9.
10. Feuerer M. Lean, but not obese, fat is enriched for a unique population of regulatory T cells that affect metabolic parameters. Nat Med. [10.1038/nm.2002]. 2009; 15: 930-9.
11. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006 Jul; 116(7): 1784-92.
12. Folco EJ, Rocha VZ, Lopez-Ilasaca M, Libby P. Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10. J Biol Chem. 2009 Sep 18; 284(38): 25569-75.
13. Lee EB. Obesity, leptin, and Alzheimer's disease. Ann N Y Acad Sci. 2011 Dec; 1243: 15-29.
14. Gomez R, Conde J, Scotece M, Gomez-Reino JJ, Lago F, Gualillo O. What's new in our understanding of the role of adipokines in rheumatic diseases? Nat Rev Rheumatol. 2011 Sep; 7(9): 528-36.
15. Gaidhu MP, Anthony NM, Patel P, Hawke TJ, Ceddia RB. Dysregulation of lipolysis and lipid metabolism in visceral and subcutaneous adipocytes by high-fat diet: role of ATGL, HSL, and AMPK. Am J Physiol Cell Physiol. 2010 Apr; 298(4): C961-71.
16. Unger RH, Scherer PE. Gluttony, sloth and the metabolic syndrome: a roadmap to lipotoxicity. Trends Endocrinol Metab. 2010 Jun; 21(6): 345-52.
17. Szczepaniak LS, Victor RG, Orci L, Unger RH. Forgotten but not gone: the rediscovery of fatty heart, the most common unrecognized disease in America. Circ Res. 2007 Oct 12; 101(8): 759-67.
18. Wang MY, Grayburn P, Chen S, Ravazzola M, Orci L, Unger RH. Adipogenic capacity and the susceptibility to type 2 diabetes and metabolic syndrome. Proc Natl Acad Sci U S A. 2008 Apr 22; 105(16): 6139-44.
19. Cavailles V, Dauvois S, L'Horset F, et al. Nuclear factor RIP140 modulates transcriptional activation by the estrogen receptor. EMBO J. 1995 Aug 1; 14(15): 3741-51.
20. Lee CH, Chinpaisal C, Wei LN. Cloning and characterization of mouse RIP140, a corepressor for nuclear orphan receptor TR2. Mol Cell Biol. 1998 Nov; 18(11): 6745-55.
21. Lee CH, Wei LN. Characterization of receptor-interacting protein 140 in retinoid receptor activities. J Biol Chem. 1999 Oct 29; 274(44): 31320-6.
22. Wei LN, Hu X, Chandra D, Seto E, Farooqui M. Receptorinteracting protein 140 directly recruits histone deacetylases for gene silencing. J Biol Chem. 2000 Dec 29; 275(52): 40782-7.
23. Vo N, Fjeld C, Goodman RH. Acetylation of nuclear hormone receptor-interacting protein RIP140 regulates binding of the transcriptional corepressor CtBP. Mol Cell Biol. 2001 Sep; 21(18): 6181-8.
24. Persaud SD, Huang WH, Park SW, Wei LN. Gene repressive activity of RIP140 through direct interaction with CDK8. Mol Endocrinol. 2011 Oct; 25(10): 1689-98.
25. Zschiedrich I, Hardeland U, Krones-Herzig A, et al. Coactivator function of RIP140 for NFkappaB/RelA-dependent cytokine gene expression. Blood. 2008 Jul 15; 112(2): 264-76.
26. Ho PC, Chuang YS, Hung CH, Wei LN. Cytoplasmic receptorinteracting protein 140 (RIP140) interacts with perilipin to regulate lipolysis. Cell Signal. 2011 Aug; 23(8): 1396-403.
27. Christian M, Kiskinis E, Debevec D, Leonardsson G, White R, Parker MG. RIP140-targeted repression of gene expression in adipocytes. Mol Cell Biol. 2005 Nov; 25(21): 9383-91.
28. Powelka AM, Seth A, Virbasius JV, et al. Suppression of oxidative metabolism and mitochondrial biogenesis by the transcriptional corepressor RIP140 in mouse adipocytes. J Clin Invest. 2006 Jan; 116(1): 125-36.
29. Christian M, White R, Parker MG. Metabolic regulation by the nuclear receptor corepressor RIP140. Trends Endocrinol Metab. 2006 Aug; 17(6): 243-50.
30. Fritah A, Christian M, Parker MG. The metabolic coregulator RIP140: an update. Am J Physiol Endocrinol Metab. 2010 Sep; 299(3): E335-40.
31. Mostaqul Huq MD, Gupta P, Wei LN. Post-translational modifications of nuclear co-repressor RIP140: a therapeutic target for metabolic diseases. Curr Med Chem. 2008; 15(4): 386-92.
32. Leonardsson G, Steel JH, Christian M, et al. Nuclear receptor corepressor RIP140 regulates fat accumulation. Proc Natl Acad Sci U S A. 2004 Jun 1; 101(22): 8437-42.
33. Berriel Diaz M, Krones-Herzig A, Metzger D, et al. Nuclear receptor cofactor receptor interacting protein 140 controls hepatic triglyceride metabolism during wasting in mice. Hepatology. 2008 Sep; 48(3): 782-91.
34. Seth A, Steel JH, Nichol D, et al. The transcriptional corepressor RIP140 regulates oxidative metabolism in skeletal muscle. Cell Metab. 2007 Sep; 6(3): 236-45.
35. Huq MD, Khan SA, Park SW, Wei LN. Mapping of phosphorylation sites of nuclear corepressor receptor interacting protein 140 by liquid chromatography-tandem mass spectroscopy. Proteomics. 2005 May; 5(8): 2157-66.
36. Huq MD, Wei LN. Post-translational modification of nuclear corepressor receptor-interacting protein 140 by acetylation. Mol Cell Proteomics. 2005 Jul; 4(7): 975-83.
37. Gupta P, Huq MD, Khan SA, Tsai NP, Wei LN. Regulation of corepressive activity of and HDAC recruitment to RIP140 by sitespecific phosphorylation. Mol Cell Proteomics. 2005 Nov; 4(11): 1776-84.
38. Huq MD, Tsai NP, Lin YP, Higgins L, Wei LN. Vitamin B6 conjugation to nuclear corepressor RIP140 and its role in gene regulation. Nat Chem Biol. 2007 Mar; 3(3): 161-5.
39. Mostaqul Huq MD, Gupta P, Tsai NP, White R, Parker MG, Wei LN. Suppression of receptor interacting protein 140 repressive activity by protein arginine methylation. EMBO J. 2006 Nov 1; 25(21): 5094-104.
40. Gupta P, Ho PC, Huq MD, Khan AA, Tsai NP, Wei LN. PKCepsilon stimulated arginine methylation of RIP140 for its nuclear-cytoplasmic export in adipocyte differentiation. PLoS One. 2008; 3(7): e2658.
41. Ho PC, Gupta P, Tsui YC, Ha SG, Huq M, Wei LN. Modulation of lysine acetylation-stimulated repressive activity by Erk2-mediated phosphorylation of RIP140 in adipocyte differentiation. Cell Signal. 2008 Oct; 20(10): 1911-9.
42. Huq MD, Ha SG, Barcelona H, Wei LN. Lysine methylation of nuclear co-repressor receptor interacting protein 140. J Proteome Res. 2009 Mar; 8(3): 1156-67.
43. Ho PC, Tsui YC, Feng X, Greaves DR, Wei LN. NF-kappaBmediated degradation of the coactivator RIP140 regulates inflammatory responses and contributes to endotoxin tolerance. Nat Immunol. 2012 Mar 4.
44. Clague MJ, Urbe S. Ubiquitin: same molecule, different degradation pathways. Cell. 2010 Nov 24; 143(5): 682-5.
45. Ho PC, Lin YW, Tsui YC, Gupta P, Wei LN. A negative regulatory pathway of GLUT4 trafficking in adipocyte: new function of RIP140 in the cytoplasm via AS160. Cell Metab. 2009 Dec; 10(6): 516-23.
46. Gregor MF, Hotamisligil GS. Thematic review series: Adipocyte Biology. Adipocyte stress: the endoplasmic reticulum and metabolic disease. J Lipid Res. 2007 Sep; 48(9): 1905-14.
47. Ho PC, Tsui YC, Lin YW, Persaud SD, Wei LN. Endothelin-1 promotes cytoplasmic accumulation of RIP140 through a ET(A)- PLCbeta-PKCepsilon pathway. Mol Cell Endocrinol. 2011 Dec 19.
48. Potenza MA, Gagliardi S, Nacci C, Carratu MR, Montagnani M. Endothelial dysfunction in diabetes: from mechanisms to therapeutic targets. Curr Med Chem. 2009; 16(1): 94-112.
49. Rehsia NS, Dhalla NS. Potential of endothelin-1 and vasopressin antagonists for the treatment of congestive heart failure. Heart Fail Rev. 2010 Jan; 15(1): 85-101.
50. Schneider JG, Tilly N, Hierl T, et al. Elevated plasma endothelin-1 levels in diabetes mellitus. Am J Hypertens. 2002 Nov; 15(11): 967-72.
51. Takahashi K, Ghatei MA, Lam HC, O'Halloran DJ, Bloom SR. Elevated plasma endothelin in patients with diabetes mellitus. Diabetologia. 1990 May; 33(5): 306-10.
52. Bedi D, Clarke KJ, Dennis JC, et al. Endothelin-1 inhibits adiponectin secretion through a phosphatidylinositol 4,5- bisphosphate/actin-dependent mechanism. Biochem Biophys Res Commun. 2006 Jun 23; 345(1): 332-9.
53. Ignatov A, Robert J, Gregory-Evans C, Schaller HC. RANTES stimulates Ca2+ mobilization and inositol trisphosphate (IP3) formation in cells transfected with G protein-coupled receptor 75. Br J Pharmacol. 2006 Nov; 149(5): 490-7.
54. Shideman CR, Hu S, Peterson PK, Thayer SA. CCL5 evokes calcium signals in microglia through a kinase-, phosphoinositide-, and nucleotide-dependent mechanism. J Neurosci Res. 2006 Jun; 83(8): 1471-84.
55. Sakamoto K, Holman GD. Emerging role for AS160/TBC1D4 and TBC1D1 in the regulation of GLUT4 traffic. Am J Physiol Endocrinol Metab. 2008 Jul; 295(1): E29-37.
56. Ho PC, Wei LN. Negative regulation of adiponectin secretion by receptor interacting protein 140 (RIP140). Cell Signal. 2012 Jan; 24(1): 71-6.